Evidence map›Paper›PMID 41811881›Full record

ArticleJournal of immunology research2026

CD47 Expression in Classic Hodgkin Lymphoma and Its Association With Tumor Microenvironment.

Xiaoyue Xiao, Lin Nong, Yiyang Luo, Jiyan Dong, Xujie Sun, Kang Jiang, Xuemin Xue, Xiaoli Feng

Abstract read
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyue XiaoDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.ORCID https://orcid.org/0009-0008-5595-3761
Lin NongDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.
Yiyang LuoDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.
Jiyan DongDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.
Xujie SunDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.
Kang JiangDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.
Xuemin XueDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.ORCID https://orcid.org/0000-0002-7842-6883
Xiaoli FengDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China, pumc.edu.cn.ORCID https://orcid.org/0000-0001-5663-6006

Funding

Beijing Hope Run Special Fund of Cancer Foundation of China LC2018L04Beijing Hope Run Special Fund of Cancer Foundation of China LC2021A21Cooperation Fund of CHCAMS Beijing & Langfang & SZCH CFA202502019
6 · The paper itself

Abstract

Cluster of differentiation 47 (CD47) has been reported to overexpress in various malignant tumors and is associated with inferior prognosis. However, the critical role of CD47 in classic Hodgkin lymphoma (CHL) and its association with immune checkpoints and tumor microenvironment (TME) remain unclear. Tumor tissues of CHL from Cancer Hospital, Chinese Academy of Medical Sciences and the public dataset from GSE17920 were analyzed. Immunohistochemistry was performed to detect the expression of CD47, programmed cell death protein 1 (PD-1), and PD ligand 1 (PD-L1) in CHL. Kaplan-Meier curves and Cox model were used for comparing the clinical outcomes of patients belonging to different subgroups. Bioinformatic analyses included differentially expressed genes (DEGs) screening, functional enrichment, and immune infiltration (CIBERSORT) were performed using GSE17920. In the study, CD47 expression was analyzed in both tumor cells (CD47tumor_score) and the TME (CD47micro_score) of CHL patients. High CD47tumor_score was associated with poorer progression-free survival (PFS) (p = 0.04). Meanwhile, high CD47micro_score was significantly correlated with worse PFS (p = 0.02). Univariate Cox regression identified high CD47micro_score as a significant predictor of inferior overall survival (OS; hazard ratio [HR] = 4.91, p = 0.03). Additionally, high CD47 expression correlated with increased PD-L1, and patients with concurrent high CD47 and positive PD-L1 of tumor cells had the shortest PFS, although this trend was not statistically significant. Importantly, a synergistic prognostic effect between CD47 and PD-L1 was that patients with high CD47 and/or PD-L1 of immune cells had significantly worse PFS than those with low expression of both markers. Analysis of public data (GSE17920) confirmed that high CD47 mRNA expression was associated with worse PFS (p = 0.02). Functional enrichment analyses revealed that high CD47 expression was linked to pathways involving chemokine signaling and immune cell migration, with increased infiltration of M1 macrophages, neutrophils, and eosinophils in the TME. CD47 might be involved in the disease progression and prognosis of CHL, it had a closely positive correlation with PD-L1. Targeting of CD47 and PD1/PDL1 might provide a promising strategy in CHL.

Indexed as

Biomarkers, TumorCD47 AntigenHodgkin DiseaseTumor MicroenvironmentAdultB7-H1 AntigenFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProgrammed Cell Death 1 ReceptorB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCD47 AntigenCD47 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD47classic Hodgkin lymphomaimmune checkpointsprognosis

Identifiers

PMID41811881
PMCPMC13140889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.